Sign in
Taking people in FrancePhase 2

Compares two maintenance treatment combinations after transplant in newly diagnosed myeloma

Compares elranatamab with lenalidomide against daratumumab with lenalidomide in adults with myeloma.

Key facts

Who runs it
Centre Hospitalier Universitaire De Nantes
Where
Amiens Cedex 1, Angers, Bayonne, Besancon Cedex, Caen Cedex 9, Clamart, Clermont-Ferrand, Compiegne, Créteil Cedex, Dijon, Epagny Metz-tessy, La Roche Sur Yon Cedex 9, Le Mans Cedex 9, Libourne Cedex, Limoges, Lorient, Lyon, Marseille, Nantes, Nice, Nimes Cedex 9, Paris, Périgueux, Perpignan Cedex, Pessac Cedex, Poitiers, Quimper Cedex, Saint Nazaire Cedex, Saint-Malo Cedex, Strasbourg, Tarbes Cedex 9, Toulouse Cedex 9, Tours, Vandoeuvre Les Nancy Cedex, and Vannes, FranceSee the 38 sites
Registry title
IFM2024-06 : A multi-center, open-label, phase 2 randomized study of elranatamab plus lenalidomide versus daratumumab plus lenalidomide as post transplantation maintenance therapy in patients with newly-diagnosed myeloma
Status
Recruiting
Phase
Phase 2
People taking part
176 people, planned
Started
19 Jun 2025
Expected to end
1 Sept 2031
Type of study
Interventional
Record updated
10 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with newly diagnosed multiple myeloma who have had one line of treatment and a stem cell autograft, to compare two maintenance treatments.

Age
18 years or older
Sex
Men and women can join
Disease stage
Documented multiple myeloma; only one line of therapy so far with at least a partial response; at least a partial response after 4 to 6 cycles of quadruplet therapy
Earlier treatment
Must have had 4 to 6 cycles of quadruplet therapy (proteasome inhibitor, IMID and anti-CD38 antibody), then high-dose melphalan and an autograft (ASCT) within 12 months of starting induction and within 6 months before the first trial dose. Must not have had any anti-BCMA therapy or post-transplant maintenance.
Biomarker or test result
NGS analysis done at myeloma diagnosis, or enough stored bone marrow for NGS analysis. Blood counts, liver and kidney tests must meet set limits.

Main reasons for not taking part

  • Any earlier anti-BCMA therapy
  • Plasma cell leukemia or POEMS syndrome
  • Active serious infection, including active HBV, HCV or SARS-CoV-2
  • Pregnant or breast-feeding women
  • Serious heart or lung disease, or earlier cancer (some exceptions)

The registry criteria, word for word

Show all 32 criteriaShow less

Who can take part

  • Male or female subjects, 18 years of age or older
  • Men must agree to not father a child and agree to use a latex condom during therapy and for 6 months after the last dose of study drug, even if they have had a successful vasectomy, if their partner is of childbearing potential
  • Voluntary written informed consent must be given before performance of any study-related procedure not part of normal medical care, with the understanding that the subject may withdraw consent at any time without prejudice to future medical care
  • Subject must have documented multiple myeloma according to International Myeloma Working Group (IMWG) criteria and have received 4 to 6 cycles of quadruplet-based therapy including proteasome inhibitor, IMID and anti CD38 monoclonal antibody
  • Subject must have received only one line of therapy and achieved at least a partial response as per IMWG 2016 criteria
  • Subject must have received high-dose melphalan and ASCT within 12 months of the start of induction therapy and be within 6 months of the last ASCT at the time of first treatment dose
  • Subject must have NGS analysis performed at time of MM diagnosis and/or adequate stored bone marrow material allowing NGS analysis (IUCT-Oncopole, Toulouse, France) in order to calibrate MRD analysis
  • Karnofsky performance status score ≥ 50% (eastern cooperative oncology group performance status ECOG score ≤ 2)
  • Subject must have clinical laboratory values meeting the following criteria during the Screening Phase : Hematology • Hemoglobin >8.0 g/dL without prior RBC transfusion within 7 days before the laboratory test; recombinant human erythropoietin use is permitted) • Platelets ≥75×109/L (without transfusion support or thrombopoietin receptor agonist within 7 days before the laboratory test) • Absolute neutrophil count ≥1.0×109/L (prior growth factor support is permitted but must be without support for 7 days for G-CSF or 14 days for pegylated-G-CSF) Chemistry • AST and ALT ≤2.5× upper limit of normal (ULN) • CrCl ≥30 mL/min based on Cockroft-Gault formula calculation or a 24-hour urine collection • Total bilirubin ≤1.5×ULN; except in participants with congenital bilirubinemia, such as Gilbert syndrome (in which case direct bilirubin ≤2×ULN is required) • Serum calcium corrected for albumin ≤14 mg/dL (≤3.5 mmol/L)
  • Women of childbearing potential must have a negative serum or urine pregnancy test within 10 to 14 days prior to therapy and repeated within 24 hours before starting study drug. They must commit to continued abstinence from heterosexual intercourse or begin 2 acceptable methods of birth control (One highly effective method and one additional effective method) used at the same time, beginning at least 4 weeks before initiation of lenalidomide treatment and continuing for at least 6 months after the last dose of Lenalidomideor Elranatamab depending on the last treatment taken. Highly effective contraceptive methods are defined as any of the following methods: combined hormonal contraception (containing estrogen and progestin) combined with ovulation inhibition (oral, intravaginal, transdermal), progestin-only hormonal contraception combined with ovulation inhibition (oral, injectable, implantable), intrauterine device (IUD), hormone-releasing intrauterine system (IUS), bilateral tubal occlusion, vasectomised partner, sexual abstinence. Women must also agree to notify pregnancy during the study

Who cannot take part

  • Subjects have received any prior anti BCMA therapy
  • Systemic treatment with strong inhibitors of CYP1A2 (fluvoxamine, enoxacin), strong inhibitors of CYP3A (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John’s wort within 14 days before the first dose of study treatment
  • Known intolerance to steroid therapy
  • Subject has had major surgery within 2 weeks before randomization or will not have fully recovered from surgery, or has surgery planned during the time the subject is expected to participate in the study. Kyphoplasty or Vertebroplasty are not considered major surgery
  • Subject have received post transplantation maintenance therapy
  • Myocardial infarction within 6 months prior to enrollment according to NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
  • History of allergy to any of the study medications, their analogues, or excipients in the various formulations
  • Clinically relevant active infection or serious co-morbid medical conditions
  • Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical, breast or prostate cancer free of disease since 5 years
  • Serious medical or psychiatric illness likely to interfere with participation in study
  • Uncontrolled diabetes mellitus
  • Incidence of gastrointestinal disease that may significantly alter the absorption of oral drugs
  • Uncontrolled hypertension
  • Subjects with known chronic obstructive pulmonary disease (COPD) with a Forced Expiratory Volume in 1 second (FEV1) < 50% of predicted normal. Note that FEV1 testing is required for patients suspected of having COPD and subjects must be excluded if FEV1 < 50% of predicted normal
  • Subjects with a history of moderate or severe persistent asthma within the past 2 years, or with uncontrolled asthma of any classification at the time of screening (Note that subjects who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed in the study)
  • Active HBV, HCV, SARS-CoV-2, HIV, or any active, uncontrolled bacterial, fungal, or viral infection. Active infections must be resolved at least 21 days prior to enrollment. Treatment with systemic anti-infective agents must have completed at least 28 days prior to enrollment. Prophylactic use of systemic agents is permitted. • COVID-19/SARS-CoV-2: SARS-CoV-2 PCR testing is mandated within 5 days prior to enrollment. Participants with positive PCR test result for SARS-CoV-2 within 5 days prior to enrollment, or suspected of having SARS-CoV-2, are excluded. • HIV: In equivocal cases, participants whose viral load is negative may be eligible. HIV seropositive participants who are otherwise healthy and at low risk for AIDS-related outcomes could be considered eligible. Potential eligibility for a specific HIV positive protocol candidate should be evaluated and discussed with the sponsor prior to screening, considering current and past CD4+ and T-cell counts, history (if any) of AIDS defining conditions (eg, opportunistic infections), status of HIV treatment and the potential for drug-drug interactions. • HBV: - Participants with a positive HBsAg test (ie, either acute or chronic active hepatitis) are excluded. - Participants with HBV antibody positivity indicating immunity, either due to vaccination or prior natural infection, are eligible. - Participants with positive anti-HBcAb but negative HBsAg and negative anti-HBsAb profile are eligible if HBV DNA is not detected. • HCV: Positive HCV antibody is indicative of infection but may not necessarily render a potential candidate ineligible, depending on clinical circumstances. If exposure to HCV is recent, HCV antibody may not have yet turned positive. In these circumstances it is recommended to test for HCV RNA. If HCV RNA is detected, the patient is not eligible
  • Subject has plasma cell leukemia (according to WHO criterion: ≥ 20% of cells in the peripheral blood with an absolute plasma cell count of more than 2 × 109/L) or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
  • Female subject who is pregnant or breast-feeding
  • Subjects unable or unwilling to undergo antithrombotic prophylactic treatment
  • Person under guardianship, trusteeship or deprived of freedom by a judicial or administrative decision
  • Subject intolerant to lenalidomide or having discontinued treatment due to any AE related to lenalidomide
  • Subject is exhibiting clinical signs of meningeal involvement of multiple myeloma

Where in France

  • Centre Hospitalier Universitaire Amiens PicardieAmiens Cedex 1, FranceTaking people
  • Centre Hospitalier Regional D'AngersAngers, FranceTaking people
  • Centre Hospitalier de la Cote BasqueBayonne, FranceTaking people
  • CHU BesanconBesancon Cedex, FranceTaking people
  • Centre Hospitalier Universitaire De Caen NormandieCaen Cedex 9, FranceTaking people
  • Hopital D Instruction Des Armées PercyClamart, FranceTaking people
  • University Hospital Of Clermont-FerrandClermont-Ferrand, FranceTaking people
  • Centre Hospitalier Intercommunal Compiegne NoyonCompiegne, FranceTaking people
  • CHU Henri MondorCréteil Cedex, FranceTaking people
  • Centre Hospitalier Universitaire de DijonDijon, FranceTaking people
  • Institut de Cancérologie de BourgogneDijon, FranceTaking people
  • Centre Hospitalier Annecy GenevoisEpagny Metz-tessy, FranceTaking people
  • Centre Hospitalier Departemental VendeeLa Roche Sur Yon Cedex 9, FranceTaking people
  • Centre Hospitalier Le MansLe Mans Cedex 9, FranceTaking people
  • Centre Hospitalier De Libourne Robert BoulinLibourne Cedex, FranceTaking people
  • Centre Hospitalier Et Universitaire de LimogesLimoges, FranceTaking people
  • Groupe Hospitalier Bretagne SudLorient, FranceTaking people
  • Centre Leon BerardLyon, FranceTaking people
  • Centre Hospitalier Regional De MarseilleMarseille, FranceTaking people
  • Centre Hospitalier Universitaire de NantesNantes, FranceTaking people
  • Centre Hospitalier Universitaire de NiceNice, FranceTaking people
  • Centre Hospitalier Universitaire De NimesNimes Cedex 9, FranceTaking people
  • Assistance Publique Hopitaux de ParisParis, FranceTaking people
  • Hopital Necker Enfants MaladesParis, FranceTaking people
  • Hopital Saint LouisParis, FranceTaking people
  • Centre Hospitalier de PerigueuxPérigueux, FranceTaking people
  • Centre Hospitalier De PerpignanPerpignan Cedex, FranceTaking people
  • Centre Hospitalier Universitaire De BordeauxPessac Cedex, FranceTaking people
  • Centre Hospitalier Universitaire de PoitiersPoitiers, FranceTaking people
  • Centre Hospitalier Intercommunal De CornouailleQuimper Cedex, FranceTaking people
  • Centre Hospitalier Saint NazaireSaint Nazaire Cedex, FranceTaking people
  • Groupe Hospitalier Rance EmeraudeSaint-Malo Cedex, FranceTaking people
  • Institut de Cancérologie Strasbourg EuropeStrasbourg, FranceTaking people
  • Centre Hospitalier Tarbes-LourdesTarbes Cedex 9, FranceTaking people
  • Oncopole Claudius RegaudToulouse Cedex 9, FranceTaking people
  • Centre Hospitalier Régional Universitaire de ToursTours, FranceTaking people
  • CHRU De NancyVandoeuvre Les Nancy Cedex, FranceTaking people
  • Centre Hospitalier Bretagne AtlantiqueVannes, FranceTaking people

About the trial

What the trial wants to find out

The primary objective is to compare the efficacy of elranatamab plus lenalidomide over daratumumab plus lenalidomide as post-transplant (post autograft) maintenance.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
IFM2024-06 : A multi-center, open-label, phase 2 randomized study of elranatamab plus lenalidomide versus daratumumab plus lenalidomide as post transplantation maintenance therapy in patients with newly-diagnosed myeloma
Plain-language title
Compares two maintenance treatment combinations after transplant in newly diagnosed myelomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
10 July 2026